---
title: "Sera Prognostics, Inc. (SERA.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/SERA.US.md"
symbol: "SERA.US"
name: "Sera Prognostics, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T11:26:56.479Z"
locales:
  - [en](https://longbridge.com/en/quote/SERA.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/SERA.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/SERA.US.md)
---

# Sera Prognostics, Inc. (SERA.US)

## Company Overview

Sera Prognostics, Inc., a women’s health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.sera.com](https://www.sera.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:13.000Z

**Overall: D (0.74)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 280 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -50.43% |  |
| Net Profit YoY | 2.57% |  |
| P/B Ratio | 1.01 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 68136181.50 |  |
| Revenue | 57000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -39.58% | E |
| Profit Margin | -56385.96% | E |
| Gross Margin | -200.00% | E |
| Revenue YoY | -50.43% | E |
| Net Profit YoY | 2.57% | C |
| Total Assets YoY | -20.85% | E |
| Net Assets YoY | -28.66% | E |
| Cash Flow Margin | 83.52% | C |
| OCF YoY | -50.43% | E |
| Turnover | 0.00 | E |
| Gearing Ratio | 27.71% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Sera Prognostics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-50.43%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "2.57%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.01",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "68136181.50",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "57000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-39.58%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-56385.96%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-200.00%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-50.43%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "2.57%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "-20.85%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-28.66%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "83.52%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-50.43%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "27.71%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -2.12 | 257/386 | - | - | - |
| PB | 1.01 | 92/386 | 1.44 | 1.19 | 0.98 |
| PS (TTM) | 1195.37 | 295/386 | 1218.78 | 1053.50 | 838.77 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-07T04:00:00.000Z

Total Analysts: **3**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 3 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.74 |
| Highest Target | 5.00 |
| Lowest Target | 5.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/SERA.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/SERA.US/norm.md)
- [Related News](https://longbridge.com/en/quote/SERA.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/SERA.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**